<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822688</url>
  </required_header>
  <id_info>
    <org_study_id>21C.030</org_study_id>
    <nct_id>NCT04822688</nct_id>
  </id_info>
  <brief_title>Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues</brief_title>
  <official_title>Analysis of Cell Count, Viability, and Immunogenicity of Deidentified Discarded Newly Diagnosed Glioblastoma Tissue and More Broadly Other Newly Diagnosed Solid Tumor Tissues From the Operating Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines tumor tissues and blood samples to aid in the development of therapies&#xD;
      for brain cancer and other solid tumors. Studying samples of blood and tissue from patients&#xD;
      with glioblastoma or other solid tumor in the laboratory may help doctors understand brain&#xD;
      tumors and better inform future treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assessment of cell yield and percentage of viable cells upon tissue receipt at the cell&#xD;
      processing facility.&#xD;
&#xD;
      II. Obtain discarded tumor tissue from surgical resections for further studies to aid in&#xD;
      development of future therapies for glioblastoma (GBM) and other solid tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Assessment of cell yield and percentage of viable cells from other solid tumor cells&#xD;
      shipped to the cell processing facility.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. An additional line of inquiry will be devoted to scientific exploration of the product's&#xD;
      immunogenicity looking at important variables in the course of manufacture.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of tissue sample during surgery. Patients also undergo collection&#xD;
      of blood sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Cell yield</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>This will be determined for each sample. Cell yield data is measured in 106and is assumed to be normally distributed. Summary statistics of mean, standard deviation, 95% confidence interval and range will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage cell viability</measure>
    <time_frame>At study completion, up to 12 months</time_frame>
    <description>Percentage cell viability will be calculated by the number of viable cells divided by the cell yield. The mean will be computed using the sum of the viable cells divided by the sum of cell yield. The range of percentage cell viability and 95% confidence interval will be provided.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Basic Science (Biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of tissue and blood samples</description>
    <arm_group_label>Basic Science (Biospecimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue, blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with GBM or other solid tumor and undergoing surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed and dated informed consent form&#xD;
&#xD;
          -  Any individual &gt;= 18 years old&#xD;
&#xD;
          -  Patients must have GBM or other solid tumor and undergoing surgery for diagnostic and&#xD;
             therapeutic purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals less than 18 years old&#xD;
&#xD;
          -  Unable to understand and give consent&#xD;
&#xD;
          -  Patients who are not surgical candidates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Judy, MD</last_name>
    <phone>215-955-7000</phone>
    <email>Kevin.Judy@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Judy, MD</last_name>
      <phone>215-955-7000</phone>
      <email>Kevin.Judy@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Judy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

